Peripheral T-cell Lymphoma - 26 Studies Found
Completed |
: A Phase 1 Study of SP-02L in Relapsed or Refractory Patients With Peripheral T-cell Lymphoma (PTCL) in Korea : Peripheral T-cell Lymphoma : 2012-09-14 :
|
Active, not recruiting |
: Phase II Study of Gemcitabine+Romidepsin in the Relapsed/Refractory Peripheral T-cell Lymphoma Patients : Peripheral T-cell Lymphoma : 2013-03-28 : Drug: Romidepsin, Gemcitabine Romidepsin 12 mg/m2 d.1,8, 15 for 6 cycles + Gemcitabine 800 mg/m2 d.1, 15 |
Completed |
: Safety Study to Evaluate Monoclonal Antibody KW-0761 in Subjects With Peripheral T-cell Lymphoma : Peripheral T-Cell Lymphoma : 2009-04-27 : Biological: KW-0761 The starting dose will be 0.1 mg/kg administered i.v. once every week for four weeks |
Completed |
: A Study of Escalating Doses of Romidepsin in Association With CHOP in the Treatment of Peripheral T-Cell Lymphomas : Peripheral T Cell Lymphoma : 2011-01-14 : Drug: Romidepsin and CHOP Romidepsin dose administered IV at day 1 and 8 or at day 1 without day 8 in co |
Recruiting |
: Efficacy and Safety of Romidepsin CHOP vs CHOP in Patients With Untreated Peripheral T-Cell Lymphoma : Peripheral T-cell Lymphoma : 2013-01-31 :
|
RECRUITING |
: CMOP Regimen and Chidamide in the Treatment of Newly Diagnosed Peripheral T-cell Lymphoma : : 2024-05-09 : Cyclophosphamide: 750 mg/m2, d1; Mitoxantrone Hydrochloride Liposome: 20 mg/m2, d1; Vincristine: 1.4 g/m2, d1 (maximum dose of 2 mg), o |